IPD Analytics has published its second installation of the Drug Pipeline and Trend Impact Report for 2020, which focuses on formulary decision making support in over 40 therapeutic areas, identifying new brands, generics, and biosimilars coming down the pipleine in the second half of 2020. Our team of executive clinical pharmacists, PhD scientists, and intellectual property attorneys track pharma litigation, clinical trial outcomes, clinical guidelines, and hundreds of sources of public information to accurately predict timing around drug launches. This information is then presented in one comprehensive report to improve formulary management strategy, assisting in P&T committee planning, making formulary inclusion decisions, and more.
As featured in our Drug Pipeline Report for 2H 2020, we have identified several key areas to watch. Listen to our recent podcast episode as our Executive Clinical Pharmacy team discusses the most impactful pipeline drugs or download the sample report now: